Effectiveness and Tolerance of Tenofovir Disoproxil Fumarate in Sub-Saharan Viral B Cirrhotic Patients
- 1 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 2 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 3 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 4 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 5 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 6 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 7 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 8 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 9 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 10 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
- 11 Hepato-Gastroenterology Department, CHU Gabriel, Bamako, Mali
Abstract
Tenofovir reduces viral load during viral cirrhosis B and improves prognosis. The aim of this study was to evaluate the effectiveness and safety of Tenofovir during the treatment of viral B cirrhosis. The study was retrospective and prospective on patients with viral B cirrhosis treated with Tenofovir in the Hepato-Gastroenterology Department of University Hospital Gabriel Touré in Bamako (Mali) and evaluated between three and six months after the start of treatment. We included 89 patients. The mean age was 44.5 ± 16 years with extremes of 18 and 90 years. The sex ratio was 1.2. At inclusion all patients had a detectable viral load with an average of 2651.96 ± 1495.85 IU/ml. Follow-up viral load was undetectable in 84.3% with patients between 3 and 6 months of treatment. The average detectable viral load was only 27.04 ± 21.05 IU/ml. There was also an improvement in hepatocellular function and few side effects. Conclusion: This study shows the interest of Tenofovir in the treatment of viral cirrhosis B with very few adverse effects.
- Balian, A. (2005) Cirrhosis and Its Complications, Collection Conduite. Doin XVI, DOIN, Paris,171 p.
- Diarra, M., Konaté, A., Soukho, A., Epouse, K., et al. (2010) Corse of Cirrhotique Disease in Hepato-Gasroenterology Service in Mali. Mali Medical, 25, 42-46.
- Dembélé, M., Maïga, I., Minta, D., et al. (2004) HBs Ag and HCV Antibodies in Chronic Liverdiseases in Hospital Services in Bamako, Mali. Bulletin de la Société de Pathologie Exotique, 97, 161-164.
- Perret, J.L., Kombila, M.J.B., Delpaporte, E., et al. (2002) HBs Ag and HCV Antibodies in Chronic Complicated Liver Diseases in Gabon. Gastroentérologie Clinique et Biologique, 26, 131-135.
- Touré, E. (2008) Aspects Epidemiological, Etiological, Clinical and Therapeutic Aspect of Cirrhosis in National Hospital of Niamey. These Medecine, Bamako.
- Saley, M. (2004) Prevalence of Chronic Liverdiseases in National Hospital of Niamey: Epidémiological, Clinical, Paraclinical and Etiologicalaspects. These Medecine, Niamey.
- Konaté, A., Diarra, M., Minta, D., et al. (2005) HCV Infection in Liver Chronicdiseases in Mali. Mali Medical, 20, 11-13.
- Ott, J.J., Stevens, G.A., Groeger, J., et al. (2012) Global Epidemiology of Hepatitis B Virus Infection: New Estimates of Age-Specific HBsAg Seroprevalence and Endemicity. Vaccine, 30, 2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116
- Zoulim, F. and Locarnini, S. (2009) Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. Gastroenterology, 137, 1593-1608. https://doi.org/10.1053/j.gastro.2009.08.063
- Van Bommel, F., Wunsche, T., Mauss, S., et al. (2004) Comparison of Adefovir and Tenofovir in the Treatment of Lamivudine-Resistant Hepatitis B Virus Infection. Hepatology, 40, 1421-1425. https://doi.org/10.1002/hep.20464
- http://www.hepfi.org/
- Bougoudogo, F., Diarra, S., Traoré, S., et al. (2001) Prevalence of HBV Serological Markers of HBV in Mali. http://www.sante.gov.ml/
- Dembélé, R. (2011) HBV Epidémiological and Serological Profile in Urba Area in Bamako. These Medecine, Bamako.
- Maïga, M.Y., Dembélé, M., Diallo, F., et al. (2002) Uper Digestive Endoscopy Valuein Cirrhhosis.Acta Endoscopica, 32, 211-218.
- Diarra, M., Konaté, A., Dembélé, M., et al. (2006) Hepatocellularcarcinoma: Epidemiological and Prognosis Aspects. Medecine Afrique Noire, 53, 23-28.